Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA ...

Novartis (NVS) shareholders agreed to the board of directors’ recommendations for all proposed resolutions at the company’s Annual General ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

This article was coproduced with Kody Kester. Since last October, Novartis' shares have lagged the S&P 500 index. The pharmaceutical company's pipeline remains robust, which could translate into ...

Below is Validea's guru fundamental report for NOVARTIS AG (ADR) (NVS). Of the 22 guru strategies we follow, NVS rates highest using our Multi-Factor Investor model based on the published strategy ...

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

After Novartis and Roche grew their sales last year, the Swiss pharma giants are handing their CEOs larger compensation packages for 2024. At Novartis, CEO Vas Narasimhan’s overall 2024 pay ...

Following the news that Liu Jiakun has won this year's Pritzker Architecture Prize, we round up 11 notable projects from the ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...